Meeting
2020 Genitourinary Cancers Symposium
The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Shabbir M.H. Alibhai
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Shabbir M.H. Alibhai , Henriette Breunis , Narhari Timilshina , Aaron Richard Hansen , Anthony M. Joshua , Padraig Richard Warde , Richard William Gregg , Neil Eric Fleshner , George Tomlinson , Sebastien J. Hotte , Urban Emmenegger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 73)
Abstract #
73
Poster Bd #
C17
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters
Poster
2019 Genitourinary Cancers Symposium
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
First Author: Alastair Thomson
Poster
2015 Genitourinary Cancers Symposium
Trends in prescribing preferences (PPrefs) of U.S.-based oncologists for patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) following docetaxel (DO).
First Author: Charles J. Ryan
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian